Published in Dermatol Surg on July 01, 2010
The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol (2012) 1.79
Benefits of total body photography and digital dermatoscopy ("two-step method of digital follow-up") in the early diagnosis of melanoma in patients at high risk for melanoma. J Am Acad Dermatol (2011) 1.09
Skin self-examinations and visual identification of atypical nevi: comparing individual and crowdsourcing approaches. Cancer Epidemiol (2013) 0.75
Total body photography versus digital dermoscopic follow-up in the diagnosis of pigmented lesions. Dermatol Surg (2011) 0.75
Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene (2017) 0.75
Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol (2005) 3.24
ABCDE--an evolving concept in the early detection of melanoma. Arch Dermatol (2005) 2.47
Melanomas arising from naevi and de novo melanomas--does origin matter? Br J Dermatol (2007) 1.83
Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer (1996) 1.71
The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol (1998) 1.70
Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. Arch Dermatol (2008) 1.64
The impact of total body photography on biopsy rate in patients from a pigmented lesion clinic. J Am Acad Dermatol (2007) 1.56
Cutaneous melanomas associated with nevi. Arch Dermatol (2003) 1.27
Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. J Am Acad Dermatol (2000) 1.17
Do all melanomas come from "moles"? A study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol (1990) 1.08
Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy. J Am Acad Dermatol (2004) 1.06
Surveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy. Br J Dermatol (2005) 1.02
Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. J Invest Dermatol (2006) 1.02
Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol (1993) 1.02
Early melanoma detection: nonuniform dermoscopic features and growth. J Am Acad Dermatol (2003) 1.01
Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet (1993) 0.96
A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. Med J Aust (1997) 0.96
Digital epiluminescence microscopy monitoring of high-risk patients. Arch Dermatol (2004) 0.94
Melanomas detected with the aid of total cutaneous photography. Br J Dermatol (2004) 0.93
Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol (2009) 0.93
Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome. J Dermatol Surg Oncol (1991) 0.92
Digital dermoscopic monitoring of atypical nevi in patients at risk for melanoma. Dermatol Surg (2007) 0.90
A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol (1993) 0.89
Detection of artificial changes in mole size by skin self-examination. J Am Acad Dermatol (2000) 0.89
Clinical characteristics of malignant melanomas developing in persons with dysplastic nevi. Cancer (1990) 0.88
Surgical prophylaxis of malignant melanoma. Ann Surg (1991) 0.88
Standardized positioning of patients (poses) for whole body cutaneous photography. J Am Acad Dermatol (2003) 0.81
Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc (2005) 2.45
Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo. J Invest Dermatol (2007) 2.11
A variant of AESOP syndrome (adenopathy and extensive skin patch overlying a plasmacytoma) in a malignant blue-cell tumor. Arch Dermatol (2012) 1.92
The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol (2012) 1.79
Case series of multiple recurrent reactive keratoacanthomas developing at surgical margins. Dermatol Surg (2009) 1.60
Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol Pharmacol (2004) 1.50
Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene (2004) 1.49
Mohs appropriate use criteria: retrospectively applied to nonmelanoma skin cancers at a single academic center. Dermatol Surg (2015) 1.43
Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol (2003) 1.39
Lepromatous leprosy and reversal reaction in a Micronesian immigrant. Int J Dermatol (2003) 1.38
Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis (2007) 1.29
Keratinocyte apoptosis in epidermal development and disease. J Invest Dermatol (2006) 1.28
Phospholipid scramblase 3 controls mitochondrial structure, function, and apoptotic response. Mol Cancer Res (2003) 1.26
Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol (2003) 1.20
Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol (2006) 1.17
UVB-induced apoptosis drives clonal expansion during skin tumor development. Carcinogenesis (2004) 1.13
Androgen receptor expression patterns in Becker's nevi: an immunohistochemical study. J Am Acad Dermatol (2008) 1.12
Dermatofibrosarcoma protuberans. J Natl Compr Canc Netw (2012) 1.11
Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Res (2007) 1.10
Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg (2007) 1.09
Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res (2010) 1.06
Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol (2006) 1.05
Metastatic melanoma - a review of current and future treatment options. Acta Derm Venereol (2015) 1.05
Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res (2012) 1.03
Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. J Am Acad Dermatol (2009) 1.03
Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res (2003) 1.00
N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. Clin Cancer Res (2007) 0.98
Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C-delta induces its activation and facilitates mitochondrial targeting of tBid. J Cell Biochem (2007) 0.97
Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias. Am J Dermatopathol (2004) 0.97
Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. J Cutan Pathol (2015) 0.96
Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. Clin Cancer Res (2009) 0.96
The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management. J Am Acad Dermatol (2012) 0.96
Role of phospholipid scramblase 3 in the regulation of tumor necrosis factor-alpha-induced apoptosis. Biochemistry (2008) 0.96
Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol (2003) 0.95
Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. Int J Cancer (2004) 0.94
Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol (2009) 0.93
Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol (2002) 0.92
The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells. Anticancer Drugs (2009) 0.92
Activation of dual apoptotic pathways in human melanocytes and protection by survivin. J Invest Dermatol (2006) 0.91
Surgical margins for melanoma in situ. J Am Acad Dermatol (2012) 0.90
Digital dermoscopic monitoring of atypical nevi in patients at risk for melanoma. Dermatol Surg (2007) 0.90
Sampling of melanocytic nevi for research purposes: a prospective, pilot study to determine effect on diagnosis. J Am Acad Dermatol (2008) 0.90
A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol (2012) 0.89
Human herpesvirus 8 and iron staining are useful in differentiating Kaposi sarcoma from interstitial granuloma annulare. Am J Clin Pathol (2007) 0.89
Colonization of adjacent stem cell compartments by mutant keratinocytes. Semin Cancer Biol (2005) 0.89
Predominant formation of heavily pigmented dermal melanocytomas resembling 'animal-type' melanomas in hepatocyte growth factor (C57BL/6 x C3H)F1 mice following neonatal UV irradiation. J Cutan Pathol (2007) 0.87
Disseminated granuloma annulare accompanying mycobacterium tuberculosis lymphadenitis. Int J Dermatol (2004) 0.86
Role of melanin in melanocyte dysregulation of reactive oxygen species. Biomed Res Int (2013) 0.86
Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements. Arch Pathol Lab Med (2012) 0.85
Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment. Dermatol Surg (2006) 0.85
Usefulness (or lack thereof) of immunophenotyping in atypical cutaneous T-cell infiltrates. Am J Clin Pathol (2006) 0.85
Chondroid syringoma: case report of a highly unusual foot tumor. Foot Ankle Int (2010) 0.84
Survivin promotion of melanoma metastasis requires upregulation of α5 integrin. Carcinogenesis (2013) 0.84
Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions. J Invest Dermatol (2012) 0.83
Onychodystrophy and tumor-stage mycosis fungoides confined to a single digit: report of a case and review of nail findings in cutaneous T-cell lymphoma. J Am Acad Dermatol (2008) 0.82
Histopathologic recognition of involved margins of lentigo maligna excised by staged excision: an interobserver comparison study. Arch Dermatol (2003) 0.82
Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J Cutan Pathol (2005) 0.82
Selenium for the prevention of cutaneous melanoma. Nutrients (2013) 0.81
Failure to detect differences in proliferation status of nevi from CDKN2A mutation carriers and non-carriers. J Invest Dermatol (2002) 0.81
Use of proliferation rate, p53 staining and perforating elastic fibers in distinguishing keratoacanthoma from hypertrophic lichen planus: a pilot study. J Cutan Pathol (2012) 0.81
Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation. Arch Dermatol (2007) 0.80
Acquired port wine stain of the upper eyelid after cluster headache. Ophthal Plast Reconstr Surg (2008) 0.80
Proteolytic cleavage of Livin (ML-IAP) in apoptotic melanoma cells potentially mediated by a non-canonical caspase. J Dermatol Sci (2006) 0.80
CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry. Cytometry B Clin Cytom (2008) 0.80
Foamy cell angiosarcoma: a rare and deceptively bland variant of cutaneous angiosarcoma. J Cutan Pathol (2010) 0.80
CD117, CK20, TTF-1, and DNA topoisomerase II-alpha antigen expression in small cell tumors. J Cutan Pathol (2004) 0.79
The role of vulvar skin biopsy in the evaluation of chronic vulvar pain. Am J Obstet Gynecol (2008) 0.79
Use of a conchal bowl flap for repair of the earlobe. Arch Dermatol (2005) 0.79
Merkel cell carcinoma, version 1.2014. J Natl Compr Canc Netw (2014) 0.79
Immunohistochemical staining with Melan-A of uninvolved sun-damaged skin shows features characteristic of lentigo maligna. Dermatol Surg (2011) 0.79
Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree. J Invest Dermatol (2008) 0.79
Report of a novel OCA2 gene mutation and an investigation of OCA2 variants on melanoma risk in a familial melanoma pedigree. J Dermatol Sci (2012) 0.79
Nevus distribution in a Utah melanoma kindred with a temperature-sensitive CDKN2A mutation. J Invest Dermatol (2005) 0.78
Melanoma mimic: a case of multiple pagetoid Spitz nevi. Arch Dermatol (2011) 0.78
Sentinel lymph node biopsy for melanoma in pregnant women. Ann Surg Oncol (2012) 0.78
Anatomic variability in superficial blood vessel and lymphatic vessel density. J Cutan Pathol (2010) 0.78
Cost-effective dynamic telepathology in the Mohs surgery laboratory utilizing iChat AV videoconferencing software. Dermatol Surg (2007) 0.77
Anal apocrine carcinoma: a case report and literature review. Am J Dermatopathol (2012) 0.77
Amifostine aminothiols and protection of keratinocyte apoptosis and DNA damage. J Invest Dermatol (2002) 0.77